Stock analysis searches answered, part 40 of 43

Boston scientific cyber sec 8-k material impact

Also searched as: cyber sec 8-k material impact "boston scientific"; "boston scientific" cyber sec 8-k material impact

This section ties “Boston scientific cyber sec 8-k material impact” to BOSTON SCIENTIFIC CORP (ticker BSX), SEC Central Index Key 885725, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-17 by BOSTON SCIENTIFIC CORP (CIK 885725) — source document:

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high-performance solutions to address unmet patient needs and reduce the cost of health care.

Financial trend for BOSTON SCIENTIFIC CORP from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $698.00 million (2022-12-31) to $2.89 billion (2025-12-31), a change of +314.3%; total assets went from $32.47 billion (2022-12-31) to $43.67 billion (2025-12-31), a change of +34.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 885725, tags Assets, ProfitLoss, Revenues; 4 periods shown, dashes mark figures BOSTON SCIENTIFIC CORP did not tag for that period.

BOSTON SCIENTIFIC CORP has 1000 filings in its recent EDGAR index, including 6 annual reports and 18 quarterly reports; its newest filing is a 8-K from 2026-10-07.

Current reports. Of the 90 8-K or 6-K reports in BOSTON SCIENTIFIC CORP’s recent EDGAR index, the 4 listed here run from 2026-08-26 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 885725 is on the EDGAR company page; the latest 10-K there is dated 2026-02-17 and the oldest filing in the recent index dates from 2020-09-14. Insider trades for BOSTON SCIENTIFIC CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Berto acquisition corp. berto acquisition corp. ii

Also searched as: "berto acquisition corp." | "berto acquisition corp. ii"

This section ties “Berto acquisition corp. berto acquisition corp. ii” to Berto Acquisition Corp. II (ticker GUAC, GUACU, GUACW), SEC Central Index Key 2081515, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14, and this view starts from filings dated on or before 2026-05-14. Nothing here is a recommendation to trade the security.

Other filings. Across its 27 recent EDGAR filings, Berto Acquisition Corp. II most often filed 3 (6), 8-K (4), SCHEDULE 13G (3), 4 (2). A selection from 2026-05-14 to 2026-05-14:

The full record for CIK 2081515 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-20. One example from this record is the 8-K filed 2026-05-18 (document). Insider trades for Berto Acquisition Corp. II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

More of the filing record for Berto Acquisition Corp. II (CIK 2081515), filings 2026-05-12 to 2026-05-14: CERT on 2026-05-14; 8-A12B on 2026-05-14; CORRESP on 2026-05-12; CORRESP on 2026-05-12; S-1/A on 2026-05-12. Each form type has a fixed purpose under SEC rules, so the mix shows what kind of events the company has been reporting.

Updated Oct 25, 2026 ET

Biomerica biomerica inc. biomerica.com

Also searched as: "biomerica" | "biomerica inc." | "biomerica.com"

This section ties “Biomerica biomerica inc. biomerica.com” to BIOMERICA INC (ticker BMRA), SEC Central Index Key 73290, an EDGAR registrant classified as “In Vitro & In Vivo Diagnostic Substances” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a DEF 14A dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-08-31 by BIOMERICA INC (CIK 73290) — source document:

We are a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Our diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions. These tests detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances that may exist in the human body at extremely low concentrations. Our products are designed to enhance patient outcomes and well-being while reducing total healthcare costs. We sell our portfolio of diagnostic products worldwide, primarily to clinical laboratories and in point-of-care settings, including physicians’ offices and over-the-counter channels.

Financial trend for BIOMERICA INC from annual reports, periods 2023-05-31 to 2026-05-31: revenue went from $5.34 million (2023-05-31) to $4.45 million (2026-05-31), a change of -16.6%; net income (loss) went from -$7.14 million (2023-05-31) to -$3.77 million (2026-05-31), a change of +47.1%; total assets went from $14.45 million (2023-05-31) to $6.76 million (2026-05-31), a change of -53.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 73290, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BIOMERICA INC did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for BIOMERICA INC (CIK 73290) lists its business address as 17571 VON KARMAN AVENUE, IRVINE, CA, which helps confirm you are on the right company’s site.

Current reports. Of the 77 8-K or 6-K reports in BIOMERICA INC’s recent EDGAR index, the 4 listed here run from 2025-12-16 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 73290 is on the EDGAR company page; the latest 10-K/A there is dated 2026-09-28 and the oldest filing in the recent index dates from 1995-09-28. Insider trades for BIOMERICA INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bright minds biosciences bright minds biosciences inc brightmindsbio.com

Also searched as: "bright minds biosciences" | "bright minds biosciences inc" | "brightmindsbio.com"

This section ties “Bright minds biosciences bright minds biosciences inc brightmindsbio.com” to BRIGHT MINDS BIOSCIENCES INC. (ticker DRUG), SEC Central Index Key 1827401, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in British Columbia, Canada. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-02. Nothing here is a recommendation to trade the security.

Financial trend for BRIGHT MINDS BIOSCIENCES INC. from annual reports, periods 2021-09-30 to 2024-09-30: net income (loss) went from -2,801,946 CAD (2021-09-30) to -2,801,946 CAD (2024-09-30), a change of +0.0%; total assets went from 20,040,368 CAD (2021-09-30) to 6,104,602 CAD (2024-09-30), a change of -69.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1827401, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures BRIGHT MINDS BIOSCIENCES INC. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for BRIGHT MINDS BIOSCIENCES INC. (CIK 1827401) lists its business address as 400 N ABERDEEN ST SUITE 900, CHICAGO, IL, which helps confirm you are on the right company’s site.

Current reports. Of the 85 8-K or 6-K reports in BRIGHT MINDS BIOSCIENCES INC.’s recent EDGAR index, the 4 listed here run from 2026-06-03 to 2026-10-02, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 179 recent EDGAR filings, BRIGHT MINDS BIOSCIENCES INC. most often filed 6-K (85), SCHEDULE 13G/A (18), D (14), UPLOAD (7). A selection from 2026-05-15 to 2026-08-14:

The full record for CIK 1827401 is on the EDGAR company page; the latest 40-F there is dated 2025-12-23 and the oldest filing in the recent index dates from 2020-10-06. Insider trades for BRIGHT MINDS BIOSCIENCES INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cadrenal therapeutics cadrenal therapeutics inc. cadrenal.com

Also searched as: "cadrenal therapeutics" | "cadrenal therapeutics inc." | "cadrenal.com"

This section ties “Cadrenal therapeutics cadrenal therapeutics inc. cadrenal.com” to Cadrenal Therapeutics, Inc. (ticker CVKD), SEC Central Index Key 1937993, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Cadrenal Therapeutics, Inc. (CIK 1937993) — source document:

We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase (“12-LOX”) platform of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005 for the treatment of immune-mediated and thrombotic disorders. Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (“HIT”), a deadly immune-mediated thrombotic disorder. CAD-1005 has been evaluated in a blinded, placebo-controlled study Phase 2 clinical trial of 24 patients as well as Phase 1 clinical trials in more than 100 patients. CAD-1005 has an orphan drug designation (“ODD”) from the FDA for the prophylaxis of thrombosis in patients with HIT, as well as an FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the EMA for the treatment of platelet-activating factor 4 disorders.

Financial trend for Cadrenal Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$8.36 million (2023-12-31) to -$13.24 million (2025-12-31), a change of -58.4%; total assets went from $778,174 (2022-12-31) to $4.33 million (2025-12-31), a change of +456.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1937993, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Cadrenal Therapeutics, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Cadrenal Therapeutics, Inc. (CIK 1937993) lists its business address as 822 A1A NORTH, PONTE VEDRA, FL, which helps confirm you are on the right company’s site.

Current reports. Of the 61 8-K or 6-K reports in Cadrenal Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1937993 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2022-07-15. Insider trades for Cadrenal Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cantor equity partners vii

Also searched as: "cantor equity partners vii"

This section ties “Cantor equity partners vii” to Cantor Equity Partners VII, Inc. (ticker CAES), SEC Central Index Key 2087965, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-15. Nothing here is a recommendation to trade the security.

Financial trend for Cantor Equity Partners VII, Inc. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$27,141 (2026-03-31) to $134,435 (2026-06-30), a change of +595.3%; total assets was tagged only for 2026-06-30 at $250.59 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2087965, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Cantor Equity Partners VII, Inc. did not tag for that period.

Cantor Equity Partners VII, Inc. has 22 filings in its recent EDGAR index, including 0 annual reports and 1 quarterly reports; its newest filing is a 8-K from 2026-10-15.

Current reports. Of the 3 8-K or 6-K reports in Cantor Equity Partners VII, Inc.’s recent EDGAR index, the 3 listed here run from 2026-06-18 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 22 recent EDGAR filings, Cantor Equity Partners VII, Inc. most often filed 3 (5), 8-K (3), SCHEDULE 13G (2), S-1/A (2). A selection from 2026-06-18 to 2026-10-15:

The full record for CIK 2087965 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-10-22. Insider trades for Cantor Equity Partners VII, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ch4 natural solutions

Also searched as: "ch4 natural solutions"

This section ties “Ch4 natural solutions” to CH4 Natural Solutions Corp (ticker MTNE, MTNE-UN, MTNE-WT), SEC Central Index Key 2044817, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands, formerly known as CH4 Natural Solutions Acquisition Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14. Nothing here is a recommendation to trade the security.

Financial trend for CH4 Natural Solutions Corp from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: net income (loss) went from -$30,900 (2025-06-30) to -$5.79 million (2026-06-30), a change of -18650.4%; total assets went from $1.11 million (2026-03-31) to $222.89 million (2026-06-30), a change of +20063.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2044817, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures CH4 Natural Solutions Corp did not tag for that period.

CH4 Natural Solutions Corp has 32 filings in its recent EDGAR index, including 0 annual reports and 2 quarterly reports; its newest filing is a SCHEDULE 13G from 2026-08-14.

Current reports. Of the 4 8-K or 6-K reports in CH4 Natural Solutions Corp’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-06-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 32 recent EDGAR filings, CH4 Natural Solutions Corp most often filed 3 (7), SCHEDULE 13G (6), S-1/A (6), 8-K (4). A selection from 2026-07-22 to 2026-08-14:

The full record for CIK 2044817 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-01-10. Insider trades for CH4 Natural Solutions Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Darkhorse technologies darkhorse technologies inc. darkhorse.inc

Also searched as: "darkhorse technologies" | "darkhorse technologies inc." | "darkhorse.inc"

This section ties “Darkhorse technologies darkhorse technologies inc. darkhorse.inc” to DarkHorse Technologies Inc. (ticker DRK), SEC Central Index Key 1591956, an EDGAR registrant classified as “Finance Services” and organised in British Columbia, Canada, formerly known as Sphere 3D Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a EFFECT dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by DarkHorse Technologies Inc. (CIK 1591956) — source document:

Sphere 3D was incorporated under the Business Corporations Act (Ontario) on May 2, 2007 as T.B. Mining Ventures Inc. On March 24, 2015, we completed a short-form amalgamation with a wholly-owned subsidiary. In connection with the short-form amalgamation, we changed our name to “Sphere 3D Corp.” Any reference to the “Company”, “Sphere 3D”, “we”, “our”, “us”, or similar terms refers to Sphere 3D Corp. and its subsidiaries. In January 2022, we commenced operations of our Bitcoin mining business and are dedicated to becoming a leader in the blockchain and cryptocurrency industry. We have established and continue to grow an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers.

Financial trend for DarkHorse Technologies Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $6.08 million (2022-12-31) to $11.18 million (2025-12-31), a change of +84.0%; net income (loss) went from -$192.80 million (2022-12-31) to -$21.48 million (2025-12-31), a change of +88.9%; total assets went from $83.02 million (2022-12-31) to $25.12 million (2025-12-31), a change of -69.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1591956, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures DarkHorse Technologies Inc. did not tag for that period.

DarkHorse Technologies Inc. has 824 filings in its recent EDGAR index, including 12 annual reports and 20 quarterly reports; its newest filing is a EFFECT from 2026-10-20.

Current reports. Of the 294 8-K or 6-K reports in DarkHorse Technologies Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-08 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1591956 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2013-11-18. Insider trades for DarkHorse Technologies Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ecovyst ecovyst inc. ecovyst.com

Also searched as: "ecovyst" | "ecovyst inc." | "ecovyst.com"

This section ties “Ecovyst ecovyst inc. ecovyst.com” to Ecovyst Inc. (ticker ECVT), SEC Central Index Key 1708035, an EDGAR registrant classified as “Chemicals & Allied Products” and organised in DE, formerly known as PQ Group Holdings Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-27 by Ecovyst Inc. (CIK 1708035) — source document:

We trace our roots to the late 1800s with our first sulfuric acid plant and the beginning of our oldest customer relationship. Our common stock is listed on the New York Stock Exchange under the stock ticker “ECVT”. Unless the context otherwise indicates, the terms “Ecovyst Inc.,” “we,” “us,” “our,” or the “Company” mean Ecovyst Inc. and our subsidiaries. We used $465.0 million of the net cash proceeds to partially repay the Senior Secured Term Loan Facility due June 2031. The results of operations, financial condition and cash flows for the Advanced Materials & Catalysts business are presented herein as discontinued operations. Refer to Note 4 to our consolidated financial statements for additional information.

Financial trend for Ecovyst Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $820.16 million (2022-12-31) to $723.51 million (2025-12-31), a change of -11.8%; net income (loss) went from $73.70 million (2022-12-31) to -$71.13 million (2025-12-31), a change of -196.5%; total assets went from $1.88 billion (2022-12-31) to $1.26 billion (2025-12-31), a change of -33.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1708035, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Ecovyst Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Ecovyst Inc. (CIK 1708035) lists its business address as 600 LEE ROAD, SUITE 200, WAYNE, PA, which helps confirm you are on the right company’s site.

Current reports. Of the 108 8-K or 6-K reports in Ecovyst Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-21 to 2026-08-24, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1708035 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2017-06-09. Insider trades for Ecovyst Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Elauwit connection elauwit connection inc. elauwit.com

Also searched as: "elauwit connection" | "elauwit connection inc." | "elauwit.com"

This section ties “Elauwit connection elauwit connection inc. elauwit.com” to Elauwit Connection, Inc. (ticker ELWT), SEC Central Index Key 2063863, an EDGAR registrant classified as “Communications Services, NEC” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-08, and this view starts from filings dated on or before 2026-06-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Elauwit Connection, Inc. (CIK 2063863) (passage 2, continuing from the earlier excerpt) — source document:

Following the closing of our initial public offering (“IPO”) in November 2025, we built a dedicated sales and marketing team that generated over 13,000 units of pipeline in less than three months. Our total pipeline as of March 20, 2026 stands at approximately 120,600 units, which represents approximately $120 million of potential network construction revenue and an estimated $26 million in annual recurring revenue, if we were able to successfully complete all of these opportunities. Within our pipeline we continue to deepen relationships with existing customers, as well as drive new logo acquisition, which now represents approximately two thirds of our pipeline. Furthermore, the portfolio holdings of ownership groups represented in our pipeline totals over 2.3 million units, providing us with meaningful expansion opportunity.

Financial trend for Elauwit Connection, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $5.25 million (2025-09-30) to $2.86 million (2026-06-30), a change of -45.6%; net income (loss) went from -$168,000 (2025-09-30) to -$3.13 million (2026-06-30), a change of -1763.7%; total assets went from $9.09 million (2025-09-30) to $10.10 million (2026-06-30), a change of +11.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2063863, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures Elauwit Connection, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Elauwit Connection, Inc. (CIK 2063863) lists its business address as 1021 SECOND AVE, COLUMBIA, SC, which helps confirm you are on the right company’s site.

Current reports. Of the 12 8-K or 6-K reports in Elauwit Connection, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-31 to 2026-06-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2063863 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2025-04-07. One example from this record is the 8-K filed 2026-08-18 (document). Insider trades for Elauwit Connection, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

First carolina financial firstcarolinabank.com

Also searched as: "first carolina financial" | "firstcarolinabank.com"

This section ties “First carolina financial firstcarolinabank.com” to First Carolina Financial Services, Inc. (ticker FCBM), SEC Central Index Key 1531193, an EDGAR registrant classified as “State Commercial Banks” and organised in NC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-18. Nothing here is a recommendation to trade the security.

Financial trend for First Carolina Financial Services, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $12.10 million (2025-06-30) to $5.54 million (2026-06-30), a change of -54.2%; net income (loss) went from $4.59 million (2025-06-30) to $5.10 million (2026-06-30), a change of +11.0%; total assets went from $3.39 billion (2025-06-30) to $3.41 billion (2026-06-30), a change of +0.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1531193, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 2 periods shown, dashes mark figures First Carolina Financial Services, Inc. did not tag for that period.

For reported results, First Carolina Financial Services, Inc.’s (CIK 1531193) latest 10-Q is dated 2026-08-14. Earnings releases appear as 8-K Item 2.02 filings; 1 are in the recent index, the newest on 2026-07-30.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for First Carolina Financial Services, Inc. (CIK 1531193) lists its business address as 2626 GLENWOOD AVENUE, RALEIGH, NC, which helps confirm you are on the right company’s site.

Current reports. Of the 3 8-K or 6-K reports in First Carolina Financial Services, Inc.’s recent EDGAR index, the 3 listed here run from 2026-06-22 to 2026-09-18, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 57 recent EDGAR filings, First Carolina Financial Services, Inc. most often filed 3 (17), 4 (15), D (10), 8-K (3). A selection from 2026-06-22 to 2026-08-14:

The full record for CIK 1531193 is on the EDGAR company page and the oldest filing in the recent index dates from 2011-11-08. Insider trades for First Carolina Financial Services, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Jatt iii acquisition jatt iii acquisition corp

Also searched as: "jatt iii acquisition" | "jatt iii acquisition corp"

This section ties “Jatt iii acquisition jatt iii acquisition corp” to JATT III Acquisition Corp (ticker JTTT), SEC Central Index Key 2145659, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D dated 2026-09-03. Nothing here is a recommendation to trade the security.

Deal and listing documents for JATT III Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 2 such filings (424B4, S-1) appear in its recent index, the newest dated 2026-08-26.

Current reports. Of the 2 8-K or 6-K reports in JATT III Acquisition Corp’s recent EDGAR index, the 2 listed here run from 2026-08-31 to 2026-09-02, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 20 recent EDGAR filings, JATT III Acquisition Corp most often filed 3 (6), SCHEDULE 13G (4), 8-K (2), SCHEDULE 13D (1). A selection from 2026-09-02 to 2026-09-03:

The full record for CIK 2145659 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-07-17. Insider trades for JATT III Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lumexa imaging lumexa imaging holdings lumexa imaging holdings inc.

Also searched as: "lumexa imaging" | "lumexa imaging holdings" | "lumexa imaging holdings inc."

This section ties “Lumexa imaging lumexa imaging holdings lumexa imaging holdings inc.” to Lumexa Imaging Holdings, Inc. (ticker LMRI), SEC Central Index Key 2071288, an EDGAR registrant classified as “Services-Medical Laboratories” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14. Nothing here is a recommendation to trade the security.

Financial trend for Lumexa Imaging Holdings, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $251.40 million (2025-06-30) to $264.16 million (2026-06-30), a change of +5.1%; net income (loss) went from -$7.23 million (2025-06-30) to $2.75 million (2026-06-30), a change of +138.0%; total assets went from $1.76 billion (2026-03-31) to $1.81 billion (2026-06-30), a change of +2.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2071288, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures Lumexa Imaging Holdings, Inc. did not tag for that period.

Lumexa Imaging Holdings, Inc. has 71 filings in its recent EDGAR index, including 1 annual reports and 2 quarterly reports; its newest filing is a SCHEDULE 13G from 2026-08-14.

Current reports. Of the 10 8-K or 6-K reports in Lumexa Imaging Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 71 recent EDGAR filings, Lumexa Imaging Holdings, Inc. most often filed 4 (17), 3 (14), 8-K (10), CORRESP (4). A selection from 2026-06-12 to 2026-08-14:

The full record for CIK 2071288 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2025-06-12. Insider trades for Lumexa Imaging Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Nexalin nexalin technology nexalin.com

Also searched as: "nexalin" | "nexalin technology" | "nexalin.com"

This section ties “Nexalin nexalin technology nexalin.com” to Nexalin Technology, Inc. (ticker NXL), SEC Central Index Key 1527352, an EDGAR registrant classified as “Electromedical & Electrotherapeutic Apparatus” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a EFFECT dated 2026-10-15. Nothing here is a recommendation to trade the security.

Financial trend for Nexalin Technology, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.32 million (2022-12-31) to $301,647 (2025-12-31), a change of -77.2%; net income (loss) went from -$1.70 million (2022-12-31) to -$8.22 million (2025-12-31), a change of -384.3%; total assets went from $7.43 million (2022-12-31) to $4.64 million (2025-12-31), a change of -37.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1527352, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Nexalin Technology, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Nexalin Technology, Inc. (CIK 1527352) lists its business address as 1776 YORKTOWN, HOUSTON, TX, which helps confirm you are on the right company’s site.

Current reports. Of the 47 8-K or 6-K reports in Nexalin Technology, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-02 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 203 recent EDGAR filings, Nexalin Technology, Inc. most often filed 8-K (47), 4 (39), S-1/A (15), UPLOAD (13). A selection from 2026-09-03 to 2026-10-15:

The full record for CIK 1527352 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2011-08-09. Insider trades for Nexalin Technology, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Npk international npk international inc. npki.com

Also searched as: "npk international" | "npk international inc." | "npki.com"

This section ties “Npk international npk international inc. npki.com” to NPK International Inc. (ticker NPKI), SEC Central Index Key 71829, an EDGAR registrant classified as “Services-Miscellaneous Equipment Rental & Leasing” and organised in DE, formerly known as NEWPARK RESOURCES INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-24. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-27 by NPK International Inc. (CIK 71829) — source document:

NPK International Inc. is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. In 2025, 66% of our revenues were generated from the rental of our recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. The remaining 34% of our 2025 revenues were generated from the sale of our manufactured recyclable composite mats to customers around the world, with power transmission being the primary end market.

Financial trend for NPK International Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$20.83 million (2022-12-31) to $38.94 million (2025-12-31), a change of +286.9%; total assets went from $714.88 million (2022-12-31) to $441.76 million (2025-12-31), a change of -38.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 71829, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures NPK International Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for NPK International Inc. (CIK 71829) lists its business address as 9320 LAKESIDE BOULEVARD, THE WOODLANDS, TX, which helps confirm you are on the right company’s site.

Current reports. Of the 220 8-K or 6-K reports in NPK International Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-29 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 71829 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2011-06-13. Insider trades for NPK International Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Picocela picocela inc. picocela.com

Also searched as: "picocela" | "picocela inc." | "picocela.com"

This section ties “Picocela picocela inc. picocela.com” to PicoCELA Inc. (ticker PCLA), SEC Central Index Key 2018462, an EDGAR registrant classified as “Electric Lighting & Wiring Equipment” and organised in Japan. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-05, and this view starts from filings dated on or before 2026-03-11. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-02-13 by PicoCELA Inc. (CIK 2018462) (passage 2, continuing from the earlier excerpt) — source document:

As such, we have only one class of shares, the Common Shares, authorized for issuance as of the date of this annual report. On October 6, 2024, our board of directors approved a forward split of our Common Shares at a ratio of 60-for-1 share. The forward split became effective on October 24, 2024. Consulting Agreement On March 31, 2023, the Company entered into a consulting and services agreement (the “Consulting Agreement”) with Spirit Advisors LLC (“Spirit Advisors”). The Consulting Agreement has an initial term of 12 months. After that, the agreement can be terminated by either party by giving 30 days’ prior written notice or by completion of the IPO. The issuance of a free warrant to Spirit Advisors pursuant to the Consulting Agreement was disapproved at the Company’s extraordinary shareholder meeting on November 29, 2024, and the Consulting Agreement was terminated upon successful completion of the IPO. Completion of IPO On January 16, 2025, the trading of the ADSs commenced on the Nasdaq Capital Market under the symbol “PCLA”.

Financial trend for PicoCELA Inc. from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from 682,121,000 JPY (2022-09-30) to 544,690,000 JPY (2025-09-30), a change of -20.1%; net income (loss) went from -5,180,000 JPY (2022-09-30) to -626,312,000 JPY (2025-09-30), a change of -11991.0%; total assets went from 1,149,212,000 JPY (2023-09-30) to 1,087,166,000 JPY (2025-09-30), a change of -5.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2018462, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures PicoCELA Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for PicoCELA Inc. (CIK 2018462) lists its business address as 2-34-5 NINGYOCHO, SANOS BUILDING,, TOKYO, Japan, which helps confirm you are on the right company’s site.

Current reports. Of the 22 8-K or 6-K reports in PicoCELA Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-06 to 2026-07-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2018462 is on the EDGAR company page; the latest 20-F there is dated 2026-02-13 and the oldest filing in the recent index dates from 2024-06-13. One example from this record is the 6-K filed 2026-07-27 (document). Insider trades for PicoCELA Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sky quarry sky quarry inc. skyquarry.com

Also searched as: "sky quarry" | "sky quarry inc." | "skyquarry.com"

This section ties “Sky quarry sky quarry inc. skyquarry.com” to Sky Quarry Inc. (ticker SKYQ), SEC Central Index Key 1812447, an EDGAR registrant classified as “Hazardous Waste Management” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a DEFA14A dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Sky Quarry Inc. (CIK 1812447) — source document:

We operate a regional refinery (the Eagle Springs Refinery) producing diesel, vacuum gas oil (VGO), naphtha and liquid paving asphalt from crude oil suppliers in the Uintah basin near Nevada and Utah. In addition to our goal of growing the refinery, we have a separate division in the development-stage (P.R. Springs) formed to deploy technologies to facilitate the recycling of waste asphalt shingles and remediation of oil-saturated sands and soil, providing sustainable refined crude products. We anticipate several benefits from the recycling and production of oil from asphalt shingles reducing the dependence on landfills for the disposal of waste and reducing dependence on foreign oil. We have developed a process for separating oil from oily sands and other oil-bearing solids utilizing a proprietary solvent, which we refer to as our ECOSolv technology or the ECOSolv process.

Financial trend for Sky Quarry Inc. from annual reports, periods 2023-12-31 to 2025-12-31: net income (loss) went from -$4.44 million (2023-12-31) to -$12.20 million (2025-12-31), a change of -175.0%; total assets went from $28.18 million (2023-12-31) to $19.21 million (2025-12-31), a change of -31.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1812447, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Sky Quarry Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Sky Quarry Inc. (CIK 1812447) lists its business address as 707 W. 700 S., WOODS CROSS, UT, which helps confirm you are on the right company’s site.

Current reports. Of the 33 8-K or 6-K reports in Sky Quarry Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-21 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1812447 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2021-07-07. Insider trades for Sky Quarry Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Skyai, inc. - common stock analyst research rating price target earnings estimates

Also searched as: "skyai, inc. - common stock" analyst research rating price target earnings estimates

This section ties “Skyai, inc. - common stock analyst research rating price target earnings estimates” to SkyAI, Inc. (ticker SKYA, SKYAW), SEC Central Index Key 1737995, an EDGAR registrant classified as “Finance Services” and organised in NV, formerly known as Sharps Technology Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SC TO-I/A dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by SkyAI, Inc. (CIK 1737995) — source document:

Sharps Technology, Inc. is a medical device sales and distribution enterprise focused on the marketing and distribution of syringe products and related drug-delivery systems. We previously designed and manufactured a portfolio of conventional and safety syringes for clinical, pharmaceutical, and specialty applications and continues to market certain remaining inventory to hospitals, clinics, healthcare providers, and medical supply organizations in both domestic and international markets. We plan to expand its distribution platform by representing established third-party manufacturers of complementary and synergistic medical products serving a common customer base. Sharps Technology is committed to maintaining compliance with all applicable regulatory and quality standards governing the marketing and distribution of medical devices, including those established by the U.S. Food and Drug Administration (FDA) and comparable international authorities.

Financial trend for SkyAI, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2025-12-31 at $204,120; net income (loss) went from -$4.64 million (2022-12-31) to -$282.50 million (2025-12-31), a change of -5988.9%; total assets went from $11.84 million (2022-12-31) to $269.08 million (2025-12-31), a change of +2172.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1737995, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures SkyAI, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SkyAI, Inc. (CIK 1737995) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

For reported results, SkyAI, Inc.’s (CIK 1737995) latest 10-Q is dated 2026-08-07 and its latest annual report (10-K) 2026-03-31.

Current reports. Of the 88 8-K or 6-K reports in SkyAI, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1737995 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2018-05-02. Insider trades for SkyAI, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Southern cross acquisition i

Also searched as: "southern cross acquisition i"

This section ties “Southern cross acquisition i” to Southern Cross Acquisition I Corp. (ticker NCO, NCOOR, NCOOU, NCOOW), SEC Central Index Key 2116230, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-09-02. Nothing here is a recommendation to trade the security.

Financial trend for Southern Cross Acquisition I Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$64,285 (2026-03-31) to -$19,738 (2026-06-30), a change of +69.3%; total assets was tagged only for 2026-06-30 at $420,992. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2116230, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Southern Cross Acquisition I Corp. did not tag for that period.

Deal and listing documents for Southern Cross Acquisition I Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 2 such filings (424B4, S-1) appear in its recent index, the newest dated 2026-07-21.

Current reports. Of the 3 8-K or 6-K reports in Southern Cross Acquisition I Corp.’s recent EDGAR index, the 3 listed here run from 2026-07-23 to 2026-07-30, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 21 recent EDGAR filings, Southern Cross Acquisition I Corp. most often filed 3 (6), 8-K (3), SCHEDULE 13G (3), 10-Q (1). A selection from 2026-07-24 to 2026-09-02:

The full record for CIK 2116230 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-04-16. Insider trades for Southern Cross Acquisition I Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Spring valley acquisition

Also searched as: "spring valley acquisition"

This section ties “Spring valley acquisition” to NUSCALE POWER Corp (ticker SMR), SEC Central Index Key 1822966, an EDGAR registrant classified as “Fabricated Plate Work (Boiler Shops)” and organised in an unstated jurisdiction, formerly known as SPRING VALLEY ACQUISITION CORP.. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-26 by NUSCALE POWER Corp (CIK 1822966) — source document:

Unless the context otherwise requires, all references in this section to “NuScale,” the “Company,” “we,” “us” or “our” refer to the consolidated operations of NuScale Corp and NuScale LLC. Overview NuScale is redefining nuclear power through the development of proprietary and innovative SMR technology that the Company believes will deliver safe, scalable, cost-effective and reliable carbon-free power. The Company’s core technology, the Light Water Nuclear Reactor NuScale Power Module™ (“NPM”), can generate 77 MWe and is premised on well-established nuclear technology principles, with a focus on the integration of components, simplification or elimination of systems and use of passive safety features. The Company believes this results in a safe and highly reliable power plant suitable to be sited close to where electricity, water desalinization, hydrogen production or process heat is needed.

Financial trend for NUSCALE POWER Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $11.80 million (2022-12-31) to $31.48 million (2025-12-31), a change of +166.7%; net income (loss) went from -$25.91 million (2022-12-31) to -$355.79 million (2025-12-31), a change of -1273.0%; total assets went from $348.63 million (2022-12-31) to $1.41 billion (2025-12-31), a change of +305.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1822966, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures NUSCALE POWER Corp did not tag for that period.

Deal and listing documents for NUSCALE POWER Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 102 such filings (424B3, 424B4, 424B5, 425, S-1) appear in its recent index, the newest dated 2026-08-11.

Current reports. Of the 107 8-K or 6-K reports in NUSCALE POWER Corp’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1822966 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2020-09-02. Insider trades for NUSCALE POWER Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tost beverages, inc.

Also searched as: "tost beverages, inc." -site:cbrands.com -site:facebook.com -site:instagram.com -site:threads.com -site:threads.net -site:linkedin.com -site:x.com -site:twitter.com -site:tiktok.com -site:youtube.com -site:youtu.be -site:reddit.com -site:t.me -site:telegram.me -site:telegram.org -site:pinterest.com -site:vimeo.com

This section ties “Tost beverages, inc.” to Tost Beverages, Inc. (ticker none listed), SEC Central Index Key 1733215, an EDGAR registrant classified as “no SIC description” and organised in DE, formerly known as Toast Beverages LLC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a D dated 2025-08-22. Nothing here is a recommendation to trade the security.

Tost Beverages, Inc. has 13 filings in its recent EDGAR index; its newest filing is a D from 2025-08-22.

What kind of filer this is matters for “Tost beverages, inc.”: Tost Beverages, Inc.’s EDGAR record from 2018-03-05 to 2025-08-22 consists only of C filings; C-AR filings; C-TR filings; C-U filings; C/A filings; Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it.

Other filings. Across its 13 recent EDGAR filings, Tost Beverages, Inc. most often filed D (5), C-AR (3), C/A (2), C-TR (1). A selection from 2023-04-28 to 2025-08-22:

The full record for CIK 1733215 is on the EDGAR company page and the oldest filing in the recent index dates from 2018-03-05. Insider trades for Tost Beverages, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ci&t

Also searched as: "ci&t"

For “Ci&t”, the matching SEC registrant is CI&T Inc, which trades as CINT and files under Central Index Key 1868995. EDGAR puts it in the “Services-Computer Programming Services” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 185 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-11 by CI&T Inc (CIK 1868995) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 55 A. Operating Results. 55 B. Liquidity and Capital Resources 66 C. Research and Development, Patents and Licenses, etc. 70 D. Trend Information 70 E. Critical Accounting Policies and Estimates 70 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 70 A. Directors and Senior Management 70 B. Compensation 72 C. Board Practices 73 D. Employees 75 E. Share Ownership 76 F. Disclosure of a registrant’s action to recover erroneously awarded compensation 76 ITEM 7. FINANCIAL INFORMATION 79 A. Consolidated Statements and Other Financial Information 79 B. Significant Changes 79 ITEM 9. THE OFFER AND LISTING 80 A. Offering and Listing Details 80 B. Plan of Distribution 80 C. Markets 80 D. Selling Shareholders 80 E. Dilution 80 F. Expenses of the Issue 80 ITEM 10.

Financial trend for CI&T Inc from annual reports, periods 2020-12-31 to 2023-12-31: revenue went from 956,519,000 BRL (2020-12-31) to 2,233,466,000 BRL (2023-12-31), a change of +133.5%; net income (loss) went from 127,654,000 BRL (2020-12-31) to 132,573,000 BRL (2023-12-31), a change of +3.9%; total assets went from 585,082,000 BRL (2020-12-31) to 2,716,891,000 BRL (2023-12-31), a change of +364.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1868995, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures CI&T Inc did not tag for that period.

CI&T Inc has 185 filings in its recent EDGAR index, including 5 annual reports and 0 quarterly reports; its newest filing is a 4 from 2026-10-13.

Current reports. Of the 46 8-K or 6-K reports in CI&T Inc’s recent EDGAR index, the 4 listed here run from 2026-04-27 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1868995 is on the EDGAR company page; the latest 20-F there is dated 2026-03-11 and the oldest filing in the recent index dates from 2021-07-06. Insider trades for CI&T Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Legend biotech

Also searched as: "legend biotech"

For “Legend biotech”, the matching SEC registrant is Legend Biotech Corp, which trades as LEGN and files under Central Index Key 1801198. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-15, across 384 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-10 by Legend Biotech Corp (CIK 1801198) — source document:

Our legal name is Legend Biotech Corporation and our commercial name is Legend Biotech. Our company was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Act (As Revised) of the Cayman Islands. Legend Biotech is a Cayman Islands holding company incorporated as a Cayman Islands exempted company and not a Chinese operating company. We operate through our operating subsidiaries located primarily in the United States, PRC and EU. Our operations in the PRC, in addition to our business presence elsewhere in the world, are enabled by our subsidiaries based therein. Information on the Company—C. Organizational Structure.” Our principal executive offices are located at 2101 Cottontail Lane, Somerset, New Jersey 08873, and our phone number is (737) 317-5050.

Financial trend for Legend Biotech Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $117.00 million (2022-12-31) to $627.24 million (2024-12-31), a change of +436.1%; net income (loss) went from -$446.35 million (2022-12-31) to -$296.80 million (2025-12-31), a change of +33.5%; total assets went from $1.33 billion (2022-12-31) to $1.73 billion (2025-12-31), a change of +30.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1801198, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Legend Biotech Corp did not tag for that period.

Legend Biotech Corp has 384 filings in its recent EDGAR index, including 6 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-10-15.

Current reports. Of the 194 8-K or 6-K reports in Legend Biotech Corp’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1801198 is on the EDGAR company page; the latest 20-F there is dated 2026-03-10 and the oldest filing in the recent index dates from 2020-03-09. Insider trades for Legend Biotech Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ovid therapeutics

Also searched as: "ovid therapeutics"

For “Ovid therapeutics”, the matching SEC registrant is Ovid Therapeutics Inc., which trades as OVID and files under Central Index Key 1636651. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-08-24, across 532 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-18 by Ovid Therapeutics Inc. (CIK 1636651) — source document:

Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. By mitigating excessive neuronal hyperexcitation with differentiated medicines, we believe we can unlock substantial scientific, therapeutic and commercial opportunities across a range of neurological and psychiatric conditions that have few therapeutic options today, both impacting patients’ lives and creating long-term stockholder value.

Financial trend for Ovid Therapeutics Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.50 million (2022-12-31) to $7.25 million (2025-12-31), a change of +382.6%; net income (loss) went from -$54.17 million (2022-12-31) to -$17.41 million (2025-12-31), a change of +67.9%; total assets went from $155.27 million (2022-12-31) to $150.93 million (2025-12-31), a change of -2.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1636651, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Ovid Therapeutics Inc. did not tag for that period.

Ovid Therapeutics Inc. has 532 filings in its recent EDGAR index, including 9 annual reports and 29 quarterly reports; its newest filing is a 144 from 2026-08-24.

Current reports. Of the 137 8-K or 6-K reports in Ovid Therapeutics Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-03 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1636651 is on the EDGAR company page; the latest 10-K there is dated 2026-03-18 and the oldest filing in the recent index dates from 2015-03-18. Insider trades for Ovid Therapeutics Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Stoke therapeutics

Also searched as: "stoke therapeutics"

For “Stoke therapeutics”, the matching SEC registrant is Stoke Therapeutics, Inc., which trades as STOK and files under Central Index Key 1623526. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was ASOthera Pharmaceuticals, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-10-21, across 628 filings on record. This is reference material, not trading advice.

Financial trend for Stoke Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $12.40 million (2022-12-31) to $184.42 million (2025-12-31), a change of +1386.7%; net income (loss) went from -$101.07 million (2022-12-31) to -$6.88 million (2025-12-31), a change of +93.2%; total assets went from $256.07 million (2022-12-31) to $418.43 million (2025-12-31), a change of +63.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1623526, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Stoke Therapeutics, Inc. did not tag for that period.

Stoke Therapeutics, Inc. has 628 filings in its recent EDGAR index, including 7 annual reports and 22 quarterly reports; its newest filing is a 144 from 2026-10-21.

Current reports. Of the 84 8-K or 6-K reports in Stoke Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-30 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 628 recent EDGAR filings, Stoke Therapeutics, Inc. most often filed 4 (275), 8-K (84), 144 (48), 3 (25). A selection from 2026-09-30 to 2026-10-21:

The full record for CIK 1623526 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2014-11-24. Insider trades for Stoke Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Trilogy metals

Also searched as: "trilogy metals"

For “Trilogy metals”, the matching SEC registrant is Trilogy Metals Inc., which trades as TMQ and files under Central Index Key 1543418. EDGAR puts it in the “Gold and Silver Ores” industry code with British Columbia, Canada as its state or country of incorporation; its earlier registered name was NovaCopper Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-17 by Trilogy Metals Inc. (CIK 1543418) — source document:

Our principal business is the exploration and development of the Upper Kobuk Mineral Projects (“Upper Kobuk Mineral Projects” or “UKMP” or “UKMP Projects”) located in the Ambler Mining District in Northwest Alaska, United States. The Upper Kobuk Mineral Projects are held by Ambler Metals LLC (“Ambler Metals”), a limited liability company owned equally by Trilogy and South32 Limited (“South32”), and is comprised of the (i) Arctic Project, which contains a high-grade polymetallic volcanogenic massive sulfide (“VMS”) deposit (“Arctic Project”); and (ii) Bornite Project, which contains a carbonate-hosted copper deposit (“Bornite Project”). Our goals include expanding mineral resources and advancing the UKMP Projects through technical, engineering and feasibility studies so that production decisions can be made on those projects.

Financial trend for Trilogy Metals Inc. from annual reports, periods 2022-11-30 to 2025-11-30: net income (loss) went from -$24.26 million (2022-11-30) to -$42.24 million (2025-11-30), a change of -74.1%; total assets went from $146.00 million (2022-11-30) to $157.30 million (2025-11-30), a change of +7.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1543418, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Trilogy Metals Inc. did not tag for that period.

Trilogy Metals Inc. has 1000 filings in its recent EDGAR index, including 12 annual reports and 39 quarterly reports; its newest filing is a 8-K from 2026-10-21.

Current reports. Of the 222 8-K or 6-K reports in Trilogy Metals Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-14 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1543418 is on the EDGAR company page; the latest 10-K there is dated 2026-02-17 and the oldest filing in the recent index dates from 2014-03-28. Insider trades for Trilogy Metals Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Willscot + modular

Also searched as: "willscot" +"modular"

For “Willscot + modular”, the matching SEC registrant is WillScot Holdings Corp, which trades as WSC and files under Central Index Key 1647088. EDGAR puts it in the “Services-Miscellaneous Equipment Rental & Leasing” industry code with DE as its state or country of incorporation; its earlier registered name was WillScot Mobile Mini Holdings Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-09, across 848 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-19 by WillScot Holdings Corp (CIK 1647088) — source document:

Unless the context otherwise requires, “we,” “us,” “our” and “Company” refers to WillScot Holdings Corporation ("WillScot") and our subsidiaries. Our Company Headquartered in Scottsdale, Arizona, we are a leading business services provider specializing in innovative and flexible turnkey temporary space solutions. Our diverse product offering includes modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers. We offer our customers a thoughtfully curated selection of solutions intended to improve the overall customer experience by making modular space and portable storage units more productive, comfortable, safe and secure for our customers with Value-Added Products (“VAPS”), such as workstations, furniture, appliances, media packages, power and solar solutions, telematics, connectivity and data solutions, security and protection products, entrance packages, electrical and lighting products, organization and space optimization assets, perimeter solutions, and other items.

Financial trend for WillScot Holdings Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.14 billion (2022-12-31) to $2.28 billion (2025-12-31), a change of +6.5%; net income (loss) went from $339.54 million (2022-12-31) to -$52.99 million (2025-12-31), a change of -115.6%; total assets went from $5.83 billion (2022-12-31) to $5.82 billion (2025-12-31), a change of -0.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1647088, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures WillScot Holdings Corp did not tag for that period.

WillScot Holdings Corp has 848 filings in its recent EDGAR index, including 11 annual reports and 33 quarterly reports; its newest filing is a 4 from 2026-10-09.

Current reports. Of the 158 8-K or 6-K reports in WillScot Holdings Corp’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1647088 is on the EDGAR company page; the latest 10-K there is dated 2026-02-19 and the oldest filing in the recent index dates from 2015-07-07. Insider trades for WillScot Holdings Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mercury systems

Also searched as: -site:facebook.com -site:fb.me -site:youtube.com -site:youtu.be -site:youtube.be -site:twitter.com -site:instagram.com -site:tiktok.com -site:vm.tiktok.com -site:t.co -site:x.com -site:reddit.com "mercury systems"

For “Mercury systems”, the matching SEC registrant is MERCURY SYSTEMS INC, which trades as MRCY and files under Central Index Key 1049521. EDGAR puts it in the “Electronic Components & Accessories” industry code with MA as its state or country of incorporation; its earlier registered name was MERCURY COMPUTER SYSTEMS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-10-21, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-08-18 by MERCURY SYSTEMS INC (CIK 1049521) — source document:

Mercury Systems is a global leader in aerospace and defense electronics, providing breakthrough capabilities in signal and data processing. With a four-decade legacy of innovation that spans silicon to systems and radio frequency (“RF”) front ends to effectors, we accelerate commercial technology adoption to deliver powerful and secure mission-critical processing solutions to the edge. We are headquartered in Andover, Massachusetts, and have multiple locations worldwide. Our end-to-end processing ecosystem, the Mercury Processing Platform, is built on technologies we have developed and acquired over 40 years. Our technologies are available as standard products or custom solutions from silicon to system scale to ensure interoperability, reduced complexity, optimized performance and speed development.

Financial trend for MERCURY SYSTEMS INC from annual reports, periods 2023-06-30 to 2026-07-03: revenue went from $973.88 million (2023-06-30) to $983.62 million (2026-07-03), a change of +1.0%; net income (loss) went from -$28.34 million (2023-06-30) to -$29.67 million (2026-07-03), a change of -4.7%; total assets went from $2.39 billion (2023-06-30) to $2.32 billion (2026-07-03), a change of -2.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1049521, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures MERCURY SYSTEMS INC did not tag for that period.

MERCURY SYSTEMS INC has 1000 filings in its recent EDGAR index, including 13 annual reports and 39 quarterly reports; its newest filing is a 144 from 2026-10-21.

Current reports. Of the 164 8-K or 6-K reports in MERCURY SYSTEMS INC’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-09-18, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1049521 is on the EDGAR company page; the latest 10-K there is dated 2026-08-18 and the oldest filing in the recent index dates from 2013-10-18. Insider trades for MERCURY SYSTEMS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alnylam and ( ikaria or gemini or c16 )

Also searched as: alnylam and ("ikaria" or "gemini" or "c16")

For “Alnylam and ( ikaria or gemini or c16 )”, the matching SEC registrant is ALNYLAM PHARMACEUTICALS, INC., which trades as ALNY and files under Central Index Key 1178670. EDGAR puts it in the “Pharmaceutical Preparations” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was ALNYLAM PHARMACEUTICALS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-06, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-12 by ALNYLAM PHARMACEUTICALS, INC. (CIK 1178670) — source document:

Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, that function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients across a broad range of disease areas and indications.

Financial trend for ALNYLAM PHARMACEUTICALS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2022-12-31 at $1.04 billion; net income (loss) went from -$1.13 billion (2022-12-31) to $313.75 million (2025-12-31), a change of +127.7%; total assets went from $3.55 billion (2022-12-31) to $4.97 billion (2025-12-31), a change of +40.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1178670, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ALNYLAM PHARMACEUTICALS, INC. did not tag for that period.

ALNYLAM PHARMACEUTICALS, INC. has 1000 filings in its recent EDGAR index, including 12 annual reports and 36 quarterly reports; its newest filing is a 4 from 2026-10-06.

Current reports. Of the 141 8-K or 6-K reports in ALNYLAM PHARMACEUTICALS, INC.’s recent EDGAR index, the 4 listed here run from 2026-03-04 to 2026-07-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1178670 is on the EDGAR company page; the latest 10-K there is dated 2026-02-12 and the oldest filing in the recent index dates from 2014-08-26. Insider trades for ALNYLAM PHARMACEUTICALS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Big sky industrial

Also searched as: "big sky industrial"

For “Big sky industrial”, the matching SEC registrant is BIG SKY INDUSTRIAL INC., which trades as BSIN and files under Central Index Key 101594. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with DE as its state or country of incorporation; its earlier registered name was US ENERGY CORP. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13D/A filed 2026-08-20, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-13 by BIG SKY INDUSTRIAL INC. (CIK 101594) — source document:

Information In this Annual Report on Form 10-K (this “Report”), we may rely on and refer to information regarding the oil and gas industry or the industrial gas industry in general from market research reports, analyst reports and other publicly available information. Although we believe that this information is reliable, we cannot guarantee the accuracy and completeness of this information, we have not independently verified any of it and we have not commissioned any of the market or survey data that is presented in this Report. Please see the “Glossary of Oil, Natural and Industrial Gas Terms” above for a list of abbreviations and definitions used throughout this Report. Our fiscal year ends on December 31st.

Financial trend for BIG SKY INDUSTRIAL INC. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$963,000 (2022-12-31) to -$14.37 million (2025-12-31), a change of -1392.6%; total assets went from $118.32 million (2022-12-31) to $40.63 million (2025-12-31), a change of -65.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 101594, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BIG SKY INDUSTRIAL INC. did not tag for that period.

BIG SKY INDUSTRIAL INC. has 1000 filings in its recent EDGAR index, including 19 annual reports and 58 quarterly reports; its newest filing is a SCHEDULE 13D/A from 2026-08-20.

Current reports. Of the 294 8-K or 6-K reports in BIG SKY INDUSTRIAL INC.’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 101594 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2007-08-14. Insider trades for BIG SKY INDUSTRIAL INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Clearway energy

Also searched as: "clearway energy"

For “Clearway energy”, the matching SEC registrant is Clearway Energy, Inc., which trades as CWEN and files under Central Index Key 1567683. EDGAR puts it in the “Electric Services” industry code with DE as its state or country of incorporation; its earlier registered name was NRG Yield, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-20, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-24 by Clearway Energy, Inc. (CIK 1567683) — source document:

Clearway Energy, Inc., together with its consolidated subsidiaries, or the Company, is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The Company was formed as a Delaware corporation on December 20, 2012. The Company is sponsored by Clearway Energy Group LLC, or CEG. The Company is one of the largest owners of clean energy generation assets in the U.S. The Company’s portfolio comprises approximately 12.9 GW of gross capacity in 27 states, including approximately 10.1 GW of wind, solar and battery energy storage systems, or BESS, and approximately 2.8 GW of dispatchable combustion-based power generation assets included in the Flexible Generation segment that provide critical grid reliability services.

Financial trend for Clearway Energy, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.19 billion (2022-12-31) to $1.43 billion (2025-12-31), a change of +20.1%; net income (loss) went from $582.00 million (2022-12-31) to $169.00 million (2025-12-31), a change of -71.0%; total assets went from $12.31 billion (2022-12-31) to $16.66 billion (2025-12-31), a change of +35.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1567683, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Clearway Energy, Inc. did not tag for that period.

Clearway Energy, Inc. has 1000 filings in its recent EDGAR index, including 9 annual reports and 28 quarterly reports; its newest filing is a 4 from 2026-10-20.

Current reports. Of the 139 8-K or 6-K reports in Clearway Energy, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-08 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1567683 is on the EDGAR company page; the latest 10-K there is dated 2026-02-24 and the oldest filing in the recent index dates from 2017-05-09. Insider trades for Clearway Energy, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Duke robotics duke robotics corp. dukeroboticsys.com

Also searched as: "duke robotics" | "duke robotics corp." | "dukeroboticsys.com"

For “Duke robotics duke robotics corp. dukeroboticsys.com”, the matching SEC registrant is DUKE Robotics Corp., which trades as DUKR, DUKRW and files under Central Index Key 1638911. EDGAR puts it in the “Aircraft” industry code with NV as its state or country of incorporation; its earlier registered name was UAS Drone Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a ARS filed 2026-10-22, across 204 filings on record. This is reference material, not trading advice.

Financial trend for DUKE Robotics Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $300,000 (2023-12-31) to $377,000 (2025-12-31), a change of +25.7%; net income (loss) went from -$1.10 million (2022-12-31) to -$1.24 million (2025-12-31), a change of -12.7%; total assets went from $2.99 million (2022-12-31) to $1.25 million (2025-12-31), a change of -58.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1638911, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures DUKE Robotics Corp. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for DUKE Robotics Corp. (CIK 1638911) lists its business address as 10 HA'RIMON ST., SCIENCE AND INDUSTRY PARK, which helps confirm you are on the right company’s site.

Current reports. Of the 31 8-K or 6-K reports in DUKE Robotics Corp.’s recent EDGAR index, the 4 listed here run from 2026-05-20 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 204 recent EDGAR filings, DUKE Robotics Corp. most often filed 10-Q (33), 8-K (31), 424B3 (28), 4 (21). A selection from 2026-10-06 to 2026-10-22:

The full record for CIK 1638911 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2015-04-10. Insider trades for DUKE Robotics Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gelteq gelteq limited gelteq.com

Also searched as: "gelteq" | "gelteq limited" | "gelteq.com"

For “Gelteq gelteq limited gelteq.com”, the matching SEC registrant is Gelteq Ltd, which trades as GELS and files under Central Index Key 1920092. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Australia as its state or country of incorporation; its earlier registered name was Gelteq Pty Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-07-06, across 71 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2025-11-17 by Gelteq Ltd (CIK 1920092) — source document:

Our registered office is located at Level 19, 644 Chapel Street, South Yarra, 3141, Australia. Our principal place of business is located at Monash Innovation Labs, G. 60, 22 Alliance Lane, Clayton 3800, Victoria, Australia Our telephone number at this address is +61 3 9087 3990. Our website address is http://www.gelteq.com . Our agent for service of process in the United States is Puglisi & Associates, 850 Library Avenue, Suite 204, Newark, Delaware 19711. We as an entity began in October 2018, but the initial research work commenced in 2014 by Gelteq’s co-founder Mr. Nathan J. Givoni. We were incorporated under the laws of the State of Victoria, Australia on October 15, 2018.

Financial trend for Gelteq Ltd from annual reports, periods 2023-06-30 to 2025-06-30: net income (loss) went from -3,506,220 AUD (2023-06-30) to -6,645,453 AUD (2025-06-30), a change of -89.5%; total assets went from 22,494,636 AUD (2023-06-30) to 21,475,155 AUD (2025-06-30), a change of -4.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1920092, tags Assets, ProfitLoss; 3 periods shown, dashes mark figures Gelteq Ltd did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Gelteq Ltd (CIK 1920092) lists its business address as LEVEL 4, SOUTH MELBOURNE VIC, which helps confirm you are on the right company’s site.

Current reports. Of the 9 8-K or 6-K reports in Gelteq Ltd’s recent EDGAR index, the 4 listed here run from 2026-05-26 to 2026-07-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1920092 is on the EDGAR company page; the latest 20-F there is dated 2025-11-17 and the oldest filing in the recent index dates from 2022-03-31. Insider trades for Gelteq Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hcw biologics hcw biologics inc. hcwbiologics.com

Also searched as: "hcw biologics" | "hcw biologics inc." | "hcwbiologics.com"

For “Hcw biologics hcw biologics inc. hcwbiologics.com”, the matching SEC registrant is HCW Biologics Inc., which trades as HCWB and files under Central Index Key 1828673. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a EFFECT filed 2026-10-09, across 340 filings on record. This is reference material, not trading advice.

Financial trend for HCW Biologics Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$14.90 million (2022-12-31) to -$7.96 million (2025-12-31), a change of +46.6%; total assets went from $46.81 million (2022-12-31) to $24.52 million (2025-12-31), a change of -47.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1828673, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures HCW Biologics Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for HCW Biologics Inc. (CIK 1828673) lists its business address as 2929 N COMMERCE PKWY, MIRAMAR, FL, which helps confirm you are on the right company’s site.

Current reports. Of the 96 8-K or 6-K reports in HCW Biologics Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-14 to 2026-09-24, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 340 recent EDGAR filings, HCW Biologics Inc. most often filed 8-K (96), 4 (94), CORRESP (17), 10-Q (16). A selection from 2026-09-09 to 2026-10-09:

The full record for CIK 1828673 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2020-10-19. Insider trades for HCW Biologics Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Leader's advantage acquisition

Also searched as: "leader's advantage acquisition"

For “Leader's advantage acquisition”, the matching SEC registrant is Leader's Advantage Acquisition Corp., which trades as LEDR, LEDRU and files under Central Index Key 2109823. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-08, across 24 filings on record. This is reference material, not trading advice.

Deal and listing documents for Leader's Advantage Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-09-21.

Current reports. Of the 2 8-K or 6-K reports in Leader's Advantage Acquisition Corp.’s recent EDGAR index, the 2 listed here run from 2026-09-23 to 2026-10-08, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 24 recent EDGAR filings, Leader's Advantage Acquisition Corp. most often filed 4 (6), 3 (6), 8-K (2), SCHEDULE 13G (2). A selection from 2026-09-23 to 2026-09-25:

The full record for CIK 2109823 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-04-29. Insider trades for Leader's Advantage Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

60 degrees pharmaceuticals 60 degrees pharmaceuticals inc 60degreespharma.com

Also searched as: "60 degrees pharmaceuticals" | "60 degrees pharmaceuticals inc" | "60degreespharma.com"

For “60 degrees pharmaceuticals 60 degrees pharmaceuticals inc 60degreespharma.com”, the matching SEC registrant is 60 DEGREES PHARMACEUTICALS, INC., which trades as SXTP, SXTPW and files under Central Index Key 1946563. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 221 filings on record. This is reference material, not trading advice.

Financial trend for 60 DEGREES PHARMACEUTICALS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $223,208 (2022-12-31) to $1.01 million (2025-12-31), a change of +350.5%; net income (loss) went from -$6.18 million (2022-12-31) to -$7.37 million (2025-12-31), a change of -19.1%; total assets went from $1.30 million (2022-12-31) to $5.37 million (2025-12-31), a change of +313.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1946563, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures 60 DEGREES PHARMACEUTICALS, INC. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for 60 DEGREES PHARMACEUTICALS, INC. (CIK 1946563) lists its business address as 1025 CONNECTICUT AVENUE NW, WASHINGTON, DC, which helps confirm you are on the right company’s site.

Current reports. Of the 48 8-K or 6-K reports in 60 DEGREES PHARMACEUTICALS, INC.’s recent EDGAR index, the 4 listed here run from 2026-09-08 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 221 recent EDGAR filings, 60 DEGREES PHARMACEUTICALS, INC. most often filed 8-K (48), 4 (27), CORRESP (26), 3 (13). A selection from 2026-08-05 to 2026-08-25:

The full record for CIK 1946563 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2022-10-18. Insider trades for 60 DEGREES PHARMACEUTICALS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Agencia comercial spirits agencia comercial spirits ltd agcctw.com

Also searched as: "agencia comercial spirits" | "agencia comercial spirits ltd" | "agcctw.com"

For “Agencia comercial spirits agencia comercial spirits ltd agcctw.com”, the matching SEC registrant is Agencia Comercial Spirits Ltd., which trades as AGCC and files under Central Index Key 2060016. EDGAR puts it in the “Wholesale-Beer, Wine & Distilled Alcoholic Beverages” industry code with Taiwan as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-16, across 55 filings on record. This is reference material, not trading advice.

Financial trend for Agencia Comercial Spirits Ltd. from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $887,310 (2023-12-31) to $6.21 million (2025-12-31), a change of +599.4%; net income (loss) went from $239,288 (2023-12-31) to $609,382 (2025-12-31), a change of +154.7%; total assets went from $3.91 million (2024-12-31) to $28.22 million (2025-12-31), a change of +621.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2060016, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Agencia Comercial Spirits Ltd. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Agencia Comercial Spirits Ltd. (CIK 2060016) lists its business address as NO. 65, LN, 114, XISHI RD., XI'AN VIL., TAICHUNG CITY, which helps confirm you are on the right company’s site.

Current reports. Of the 19 8-K or 6-K reports in Agencia Comercial Spirits Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-24 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 55 recent EDGAR filings, Agencia Comercial Spirits Ltd. most often filed 6-K (19), 3 (7), CORRESP (5), F-1/A (4). A selection from 2026-06-17 to 2026-08-27:

The full record for CIK 2060016 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2025-03-31. Insider trades for Agencia Comercial Spirits Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alpha cognition alpha cognition inc. alphacognition.com

Also searched as: "alpha cognition" | "alpha cognition inc." | "alphacognition.com"

For “Alpha cognition alpha cognition inc. alphacognition.com”, the matching SEC registrant is Alpha Cognition Inc., which trades as ACOG and files under Central Index Key 1655923. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with British Columbia, Canada as its state or country of incorporation; its earlier registered name was Neurodyn Cognition Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-19, across 215 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by Alpha Cognition Inc. (CIK 1655923) — source document:

We are a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease (“AD”), for which there are limited or no treatment options. We focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation. Our commercial development program for ZUNVEYL is primarily focused on building a long-term care (“LTC”) commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors (“AChEI”) treatments, and franchising potential additional indications and new products. We launched ZUNVEYL on March 19, 2025 and will target the largest volume nursing homes specializing in Alzheimer’s Disease, leveraging an account-based sales team with demonstrated success in LTC, positioning ZUNVEYL with Medicare payors, and developing strategic and clinical partnerships with consultant pharmacists and long-term care pharmacies.

Financial trend for Alpha Cognition Inc. from annual reports, periods 2023-12-31 to 2025-12-31: revenue was tagged only for 2025-12-31 at $10.22 million; net income (loss) went from -$13.76 million (2023-12-31) to -$20.67 million (2025-12-31), a change of -50.2%; total assets went from $2.45 million (2023-12-31) to $79.73 million (2025-12-31), a change of +3151.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1655923, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Alpha Cognition Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Alpha Cognition Inc. (CIK 1655923) lists its business address as 1452 HUGHES RD., STE. 200, GRAPEVINE, TX, which helps confirm you are on the right company’s site.

Current reports. Of the 26 8-K or 6-K reports in Alpha Cognition Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-27 to 2026-06-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1655923 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2015-10-16. Insider trades for Alpha Cognition Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ambitions enterprise

Also searched as: "ambitions enterprise"

For “Ambitions enterprise”, the matching SEC registrant is AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C, which trades as AHMA and files under Central Index Key 2010959. EDGAR puts it in the “Services-Amusement & Recreation Services” industry code with United Arab Emirates as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-05-07, across 41 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-30 by AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C (CIK 2010959) — source document:

AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C was incorporated on November 2, 2023, as an exempted company with limited liability in the Cayman Islands. On October 26, 2023, Ambitions Dubai was incorporated in the UAE and was acquired by the Company on December 10, 2023. On October 10, 2007, Hunter Dubai was incorporated as a company with limited liability organized pursuant to the laws of the Emirate of Dubai. On March 16, 2008, Multiple Dubai was incorporated as a company with limited liability organized pursuant to the laws of the Emirate of Dubai. On November 21, 2023, Ambitions Dubai acquired 100% of the equity interests in Hunter Dubai and Multiple Dubai from their respective shareholders.

Financial trend for AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $18.63 million (2023-12-31) to $20.23 million (2025-12-31), a change of +8.6%; net income (loss) went from $1.42 million (2023-12-31) to $1.22 million (2025-12-31), a change of -13.9%; total assets went from $9.99 million (2024-12-31) to $15.05 million (2025-12-31), a change of +50.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2010959, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C did not tag for that period.

AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C has 41 filings in its recent EDGAR index, including 1 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-05-07.

Current reports. Of the 5 8-K or 6-K reports in AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C’s recent EDGAR index, the 4 listed here run from 2025-12-08 to 2026-05-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2010959 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2024-03-12. Insider trades for AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ameriserv financial ameriserv financial inc ameriserv.com

Also searched as: "ameriserv financial" | "ameriserv financial inc" | "ameriserv.com"

For “Ameriserv financial ameriserv financial inc ameriserv.com”, the matching SEC registrant is AMERISERV FINANCIAL INC /PA/, which trades as ASRV and files under Central Index Key 707605. EDGAR puts it in the “National Commercial Banks” industry code with PA as its state or country of incorporation; its earlier registered name was USBANCORP INC /PA/. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 1005 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-18 by AMERISERV FINANCIAL INC /PA/ (CIK 707605) — source document:

The Company functions primarily as a coordinating and servicing unit for its subsidiary entity in general management, accounting and taxes, loan review, internal audit, investment accounting, marketing and risk management. As a bank holding company, the Company is subject to supervision and regular examination by the Federal Reserve Bank of Philadelphia and the Pennsylvania Department of Banking and Securities (PDB). The Company is also under the jurisdiction of the Securities and Exchange Commission (SEC) for matters relating to registered offerings and sales of its securities under the Securities Act of 1933, as amended, and the disclosure and regulatory requirements of the Securities Exchange Act of 1934, as amended. The Company’s common stock is listed on The NASDAQ Stock Market under the trading symbol “ASRV,” and the Company is subject to the NASDAQ rules applicable to listed companies.

Financial trend for AMERISERV FINANCIAL INC /PA/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $14.74 million (2022-12-31) to $14.63 million (2025-12-31), a change of -0.7%; net income (loss) went from $7.45 million (2022-12-31) to $5.61 million (2025-12-31), a change of -24.7%; total assets went from $1.36 billion (2022-12-31) to $1.45 billion (2025-12-31), a change of +6.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 707605, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures AMERISERV FINANCIAL INC /PA/ did not tag for that period.

For reported results, AMERISERV FINANCIAL INC /PA/’s (CIK 707605) latest 10-Q is dated 2026-08-14 and its latest annual report (10-K) 2026-03-18. Earnings releases appear as 8-K Item 2.02 filings; 59 are in the recent index, the newest on 2026-10-20.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for AMERISERV FINANCIAL INC /PA/ (CIK 707605) lists its business address as MAIN & FRANKLIN STS, JOHNSTOWN, PA, which helps confirm you are on the right company’s site.

Current reports. Of the 159 8-K or 6-K reports in AMERISERV FINANCIAL INC /PA/’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 707605 is on the EDGAR company page; the latest 10-K there is dated 2026-03-18 and the oldest filing in the recent index dates from 2012-05-15. Insider trades for AMERISERV FINANCIAL INC /PA/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Amr resources acquisition amr resources acquisition corp

Also searched as: "amr resources acquisition" | "amr resources acquisition corp"

For “Amr resources acquisition amr resources acquisition corp”, the matching SEC registrant is AMR Resources Acquisition Corp., which trades as AMAC, AMACU, AMACW and files under Central Index Key 2110119. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-04, across 19 filings on record. This is reference material, not trading advice.

Financial trend for AMR Resources Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$60,953 (2026-03-31) to -$33,181 (2026-06-30), a change of +45.6%; total assets was tagged only for 2026-06-30 at $371,636. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2110119, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures AMR Resources Acquisition Corp. did not tag for that period.

Deal and listing documents for AMR Resources Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-07-17.

Current reports. Of the 3 8-K or 6-K reports in AMR Resources Acquisition Corp.’s recent EDGAR index, the 3 listed here run from 2026-07-21 to 2026-09-04, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 19 recent EDGAR filings, AMR Resources Acquisition Corp. most often filed 3 (6), 8-K (3), 10-Q (1), SCHEDULE 13G (1). A selection from 2026-07-16 to 2026-08-27:

The full record for CIK 2110119 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-27. Insider trades for AMR Resources Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aprea therapeutics aprea therapeutics inc. aprea.com

Also searched as: "aprea therapeutics" | "aprea therapeutics inc." | "aprea.com"

For “Aprea therapeutics aprea therapeutics inc. aprea.com”, the matching SEC registrant is Aprea Therapeutics, Inc., which trades as APRE and files under Central Index Key 1781983. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-08-28, across 444 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-16 by Aprea Therapeutics, Inc. (CIK 1781983) — source document:

On September 20, 2019, we consummated a reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB were exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics, Inc. As a result, Aprea Therapeutics AB became a wholly-owned subsidiary of Aprea Therapeutics, Inc. Prior to our acquisition of Atrin Pharmaceuticals Inc. (“Atrin”) in May 2022, we were engaged in the clinical development of cancer therapeutics that related to the mutant p53 tumor suppressor protein. Following our acquisition of Atrin, we enhanced our pipeline and shifted the focus of our activities to the assets acquired from Atrin and those developed in house.

Financial trend for Aprea Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$112.66 million (2022-12-31) to -$12.60 million (2025-12-31), a change of +88.8%; total assets went from $30.16 million (2022-12-31) to $15.93 million (2025-12-31), a change of -47.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1781983, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Aprea Therapeutics, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Aprea Therapeutics, Inc. (CIK 1781983) lists its business address as 3805 OLD EASTON ROAD, DOYLESTOWN, PA, which helps confirm you are on the right company’s site.

Current reports. Of the 93 8-K or 6-K reports in Aprea Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-17 to 2026-08-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1781983 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2019-07-12. Insider trades for Aprea Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Arcadia biosciences arcadia biosciences inc. arcadiabio.com

Also searched as: "arcadia biosciences" | "arcadia biosciences inc." | "arcadiabio.com"

For “Arcadia biosciences arcadia biosciences inc. arcadiabio.com”, the matching SEC registrant is Arcadia Biosciences, Inc., which trades as RKDA and files under Central Index Key 1469443. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-8 filed 2026-09-30, across 596 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by Arcadia Biosciences, Inc. (CIK 1469443) — source document:

On May 16, 2024, Arcadia sold the GoodWheat™ brand to Above Food for net consideration of $3.7 million. The strategic decision to sell GoodWheat enabled the Company to monetize its intellectual property early. The assets sold consisted primarily of grain and finished goods inventories, formulations and trademarks. Refer to Notes 4 and 8 to the consolidated financial statements for further details of the transaction. On December 4, 2024, Arcadia, Roosevelt Resources LP (“Roosevelt” or the “Partnership”) and Elliott Roosevelt, Jr. and David A. Roosevelt, in their capacities as representatives of the limited partners of the Partnership entered into a Securities Exchange Agreement (as it may be amended from time to time, the “Exchange Agreement”) providing for the combination of the two companies in an all-stock transaction.

Financial trend for Arcadia Biosciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $7.42 million (2022-12-31) to $4.86 million (2025-12-31), a change of -34.5%; net income (loss) went from -$15.38 million (2022-12-31) to -$2.34 million (2025-12-31), a change of +84.8%; total assets went from $28.92 million (2022-12-31) to $6.55 million (2025-12-31), a change of -77.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1469443, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Arcadia Biosciences, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Arcadia Biosciences, Inc. (CIK 1469443) lists its business address as 5956 SHERRY LANE, DALLAS, TX, which helps confirm you are on the right company’s site.

Current reports. Of the 138 8-K or 6-K reports in Arcadia Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-10 to 2026-09-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1469443 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2009-08-04. Insider trades for Arcadia Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ark restaurants ark restaurants corp arkrestaurants.com

Also searched as: "ark restaurants" | "ark restaurants corp" | "arkrestaurants.com"

For “Ark restaurants ark restaurants corp arkrestaurants.com”, the matching SEC registrant is ARK RESTAURANTS CORP, which trades as ARKR and files under Central Index Key 779544. EDGAR puts it in the “Retail-Eating Places” industry code with NY as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-09-28, across 776 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-12-18 by ARK RESTAURANTS CORP (CIK 779544) — source document:

We are a New York corporation formed in 1983. As of the fiscal year ended September 27, 2025, we owned and/or operated 16 restaurants and bars, 12 fast food concepts and catering operations through our subsidiaries. Three of our restaurant and bar facilities are located in New York City, one is located in Washington, D.C., five are located in Las Vegas, Nevada, one is located in Atlantic City, New Jersey, four are located on the east coast of Florida and two are located on the Gulf Coast of Alabama. Our restaurants are typically larger, destination properties intended to benefit from high patron traffic attributable to the uniqueness of the location and catered events.

Financial trend for ARK RESTAURANTS CORP from annual reports, periods 2022-10-01 to 2025-09-27: revenue went from $183.67 million (2022-10-01) to $165.75 million (2025-09-27), a change of -9.8%; net income (loss) went from $9.28 million (2022-10-01) to -$11.47 million (2025-09-27), a change of -223.5%; total assets went from $209.53 million (2022-10-01) to $133.50 million (2025-09-27), a change of -36.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 779544, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures ARK RESTAURANTS CORP did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for ARK RESTAURANTS CORP (CIK 779544) lists its business address as 85 FIFTH AVENUE, NEW YORK, NY, which helps confirm you are on the right company’s site.

Current reports. Of the 204 8-K or 6-K reports in ARK RESTAURANTS CORP’s recent EDGAR index, the 4 listed here run from 2026-03-18 to 2026-08-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 779544 is on the EDGAR company page; the latest 10-K there is dated 2025-12-18 and the oldest filing in the recent index dates from 1994-02-14. Insider trades for ARK RESTAURANTS CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Arko petroleum arko petroleum corp. arkopetroleum.com

Also searched as: "arko petroleum" | "arko petroleum corp." | "arkopetroleum.com"

For “Arko petroleum arko petroleum corp. arkopetroleum.com”, the matching SEC registrant is ARKO Petroleum Corp., which trades as APC and files under Central Index Key 2080921. EDGAR puts it in the “Wholesale-Petroleum & Petroleum Products (No Bulk Stations)” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 60 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-30 by ARKO Petroleum Corp. (CIK 2080921) — source document:

ARKO Petroleum Corp. is a growth-oriented, fuel distribution company and one of the largest wholesale fuel distributors by gallons in North America, supplying customers in approximately 3,500 locations in the District of Columbia and more than 30 states across the Mid-Atlantic, Midwestern, Northeastern, Southeastern, and Southwestern United States (“U.S.”). Based in Richmond, Virginia, we were formed in July 2025 as a Delaware corporation and a wholly owned subsidiary of ARKO Corp. (“ARKO Parent”), which is one of the largest operators of convenience stores in the U.S., whose common stock is listed on the Nasdaq Stock Market (“Nasdaq”) under the symbol “ARKO.” We primarily engage in wholesale activity, which includes the supply of fuel to gas stations operated by third-party dealers; fleet fueling, which includes the operation of proprietary and third-party cardlock locations (unstaffed fueling locations) and the issuance of proprietary fuel cards that provide customers access to a nationwide network of fueling sites, and the wholesale distribution of fuel to substantially all of ARKO Parent’s retail convenience stores that sell fuel (“ARKO Retail Sites”).

Financial trend for ARKO Petroleum Corp. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $1.44 billion (2025-06-30) to $1.84 billion (2026-06-30), a change of +27.4%; net income (loss) went from $10.03 million (2025-06-30) to $12.24 million (2026-06-30), a change of +22.0%; total assets went from $1.37 billion (2026-03-31) to $1.39 billion (2026-06-30), a change of +0.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2080921, tags Assets, ProfitLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 3 periods shown, dashes mark figures ARKO Petroleum Corp. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for ARKO Petroleum Corp. (CIK 2080921) lists its business address as 8565 MAGELLAN PKWY., STE 400, RICHMOND, VA, which helps confirm you are on the right company’s site.

Current reports. Of the 8 8-K or 6-K reports in ARKO Petroleum Corp.’s recent EDGAR index, the 4 listed here run from 2026-05-07 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2080921 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2025-09-15. Insider trades for ARKO Petroleum Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ategrity specialty ategrity specialty holdings ategrity.com

Also searched as: "ategrity specialty" | "ategrity specialty holdings" | "ategrity.com"

For “Ategrity specialty ategrity specialty holdings ategrity.com”, the matching SEC registrant is Ategrity Specialty Insurance Co Holdings, which trades as ASIC and files under Central Index Key 2040491. EDGAR puts it in the “Fire, Marine & Casualty Insurance” industry code with DE as its state or country of incorporation; its earlier registered name was Ategrity Specialty Holdings LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21 (this view begins at filings dated on or before 2026-06-11), across 62 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-06 by Ategrity Specialty Insurance Co Holdings (CIK 2040491) (passage 2, continuing from the earlier excerpt) — source document:

For the year ended December 31, 2025, we generated $581.5 million in gross written premiums and reported a combined ratio of 88.2%. As of December 31, 2025, stockholders’ equity was $614.3 million. Both Ategrity Specialty and Ategrity Specialty Insurance Limited (“Ategrity Limited”) hold an “A-” (Excellent) (Outlook Positive) financial strength rating from A.M. Best. Our Market We operate exclusively within the E&S market, a segment of the property and casualty insurance industry that provides coverage for risks that are typically unavailable in the admitted market. E&S carriers benefit from broad regulatory flexibility with respect to rate and form, which supports tailored product design and underwriting discipline. Within the E&S market, we focus on SMB accounts.

Financial trend for Ategrity Specialty Insurance Co Holdings from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $116.10 million (2025-09-30) to $148.48 million (2026-06-30), a change of +27.9%; net income (loss) went from $22.66 million (2025-09-30) to $33.45 million (2026-06-30), a change of +47.6%; total assets went from $1.45 billion (2025-09-30) to $1.66 billion (2026-06-30), a change of +15.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2040491, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Ategrity Specialty Insurance Co Holdings did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Ategrity Specialty Insurance Co Holdings (CIK 2040491) lists its business address as 9 WEST 57TH STREET, 33RD FLOOR, NEW YORK, NY, which helps confirm you are on the right company’s site.

Current reports. Of the 13 8-K or 6-K reports in Ategrity Specialty Insurance Co Holdings’s recent EDGAR index, the 4 listed here run from 2026-02-19 to 2026-06-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2040491 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2024-11-20. One example from this record is the 8-K filed 2026-07-29 (document).

Updated Oct 25, 2026 ET

Attovia therapeutics attovia therapeutics inc.

Also searched as: "attovia therapeutics" | "attovia therapeutics inc."

For “Attovia therapeutics attovia therapeutics inc.”, the matching SEC registrant is Attovia Therapeutics, Inc., which trades as ATTO and files under Central Index Key 2058707. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4/A filed 2026-10-08, across 56 filings on record. This is reference material, not trading advice.

Financial trend for Attovia Therapeutics, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $0 (2025-06-30) to $450,000 (2026-06-30); net income (loss) went from -$14.44 million (2025-06-30) to -$20.69 million (2026-06-30), a change of -43.3%; total assets was tagged only for 2026-06-30 at $128.35 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2058707, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Attovia Therapeutics, Inc. did not tag for that period.

Attovia Therapeutics, Inc. has 56 filings in its recent EDGAR index, including 0 annual reports and 1 quarterly reports; its newest filing is a 4/A from 2026-10-08.

Current reports. Of the 2 8-K or 6-K reports in Attovia Therapeutics, Inc.’s recent EDGAR index, the 2 listed here run from 2026-08-06 to 2026-09-02, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 56 recent EDGAR filings, Attovia Therapeutics, Inc. most often filed 3 (19), 4 (14), 4/A (4), 3/A (2). A selection from 2026-09-02 to 2026-10-08:

The full record for CIK 2058707 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-12-19. Insider trades for Attovia Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aura biosciences aura biosciences inc. aurabiosciences.com

Also searched as: "aura biosciences" | "aura biosciences inc." | "aurabiosciences.com"

For “Aura biosciences aura biosciences inc. aurabiosciences.com”, the matching SEC registrant is Aura Biosciences, Inc., which trades as AURA and files under Central Index Key 1501796. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-01, across 380 filings on record. This is reference material, not trading advice.

Financial trend for Aura Biosciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$58.76 million (2022-12-31) to -$106.19 million (2025-12-31), a change of -80.7%; total assets went from $223.94 million (2022-12-31) to $169.43 million (2025-12-31), a change of -24.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1501796, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Aura Biosciences, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Aura Biosciences, Inc. (CIK 1501796) lists its business address as 80 GUEST STREET, BOSTON, MA, which helps confirm you are on the right company’s site.

Current reports. Of the 52 8-K or 6-K reports in Aura Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-11 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 380 recent EDGAR filings, Aura Biosciences, Inc. most often filed 4 (112), 8-K (52), 144 (44), 3 (24). A selection from 2026-09-01 to 2026-10-01:

The full record for CIK 1501796 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2010-09-21. Insider trades for Aura Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Avalo therapeutics inc avalo therapeutics avalotx.com

Also searched as: "avalo therapeutics inc" | "avalo therapeutics" | "avalotx.com"

For “Avalo therapeutics inc avalo therapeutics avalotx.com”, the matching SEC registrant is Avalo Therapeutics, Inc., which trades as AVTX and files under Central Index Key 1534120. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Cerecor Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 1005 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-23 by Avalo Therapeutics, Inc. (CIK 1534120) — source document:

We are a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (“mAb”) is in a Phase 2 clinical trial for hidradenitis suppurativa (“HS”). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. Our current focus is on completing the Phase 2 (“LOTUS”) trial evaluating abdakibart (AVTX-009) in HS, preparing for the anticipated topline data readout in the second quarter of 2026, and planning for our Phase 3 trial(s). Our Strategy Our strategy for increasing stockholder value includes: • Advancing our pipeline through development to regulatory approval—notably and in the near term, by completing our Phase 2 LOTUS trial in HS, preparing to initiate our pivotal trial(s) pending the readout of the Phase 2 LOTUS trial results and considering further indication expansion for abdakibart (AVTX-009); • Acquiring or in-licensing rights to and/or developing targeted, complementary differentiated preclinical and clinical stage compounds that treat immune-mediated inflammatory disease; and • Opportunistically out-licensing rights to compounds, indications or geographies.

Financial trend for Avalo Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$41.66 million (2022-12-31) to -$78.26 million (2025-12-31), a change of -87.9%; total assets went from $33.37 million (2022-12-31) to $116.46 million (2025-12-31), a change of +249.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1534120, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Avalo Therapeutics, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Avalo Therapeutics, Inc. (CIK 1534120) lists its business address as 1500 LIBERTY RIDGE DRIVE, WAYNE, PA, which helps confirm you are on the right company’s site.

Current reports. Of the 174 8-K or 6-K reports in Avalo Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-12 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1534120 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2017-04-04. Insider trades for Avalo Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bk technologies bk technologies corporation bktechnologies.com

Also searched as: "bk technologies" | "bk technologies corporation" | "bktechnologies.com"

For “Bk technologies bk technologies corporation bktechnologies.com”, the matching SEC registrant is BK Technologies Corp, which trades as BKTI and files under Central Index Key 2186. EDGAR puts it in the “Radio & Tv Broadcasting & Communications Equipment” industry code with NV as its state or country of incorporation; its earlier registered name was BK Technologies, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-13, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by BK Technologies Corp (CIK 2186) — source document:

BK Technologies Corporation (NYSE American: BKTI) (together with its wholly owned subsidiaries, “BK,” the “Company,” “we” or “us”) is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by our operating subsidiary. In business for over 70 years, BK operates two key product group offerings: Radio and Solutions. The Radio product group designs, manufactures and markets wireless communications products and related accessories consisting of two-way land mobile radios (“LMRs”). Two-way LMRs can be radios that are hand-held (portable) or installed in vehicles (mobile). Generally, BK Technologies-branded products serve government markets, including, but not limited to, emergency response, public safety, homeland security and military customers of federal, state and municipal government agencies, as well as various industrial and commercial enterprises.

Financial trend for BK Technologies Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $50.95 million (2022-12-31) to $74.09 million (2023-12-31), a change of +45.4%; net income (loss) went from -$11.63 million (2022-12-31) to $13.54 million (2025-12-31), a change of +216.4%; total assets went from $48.83 million (2022-12-31) to $63.76 million (2025-12-31), a change of +30.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2186, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BK Technologies Corp did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for BK Technologies Corp (CIK 2186) lists its business address as 7100 TECHNOLOGY DRIVE, WEST MELBOURNE, FL, which helps confirm you are on the right company’s site.

Current reports. Of the 250 8-K or 6-K reports in BK Technologies Corp’s recent EDGAR index, the 4 listed here run from 2026-06-18 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2186 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2004-07-23. Insider trades for BK Technologies Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET